Salud financiera de hoja de balance de Deciphera Pharmaceuticals
Salud financiera controles de criterios 6/6
Deciphera Pharmaceuticals tiene un patrimonio de los accionistas total de $350.9M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $473.6M y $122.7M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$306.22m |
| Patrimonio | US$350.92m |
| Total pasivo | US$122.65m |
| Activos totales | US$473.57m |
Actualizaciones recientes sobre salud financiera
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Recent updates
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%
Feb 11
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Feb 05Deciphera to expand geographic reach and clinical potential of ripretinib
Jan 11Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price
Dec 15Deciphera completes enrollment in late-stage study of ripretinib in GIST patients
Nov 30Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($381.1M) de DCPH superan a sus pasivos a corto plazo ($100.3M).
Pasivo a largo plazo: Los activos a corto plazo de DCPH ($381.1M) superan a sus pasivos a largo plazo ($22.4M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: DCPH está libre de deudas.
Reducción de la deuda: DCPH no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 0.5%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: DCPH tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: DCPH dispone de suficiente cash runway para 2.3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 12.8% cada año.